Vol 94, No 4 (2023)
Research paper
Published online: 2023-03-16

open access

Page views 2043
Article views/downloads 345
Get Citation

Connect on Social Media

Connect on Social Media

CoronaVac vaccine does not affect ovarian reserve

Ayşe Rabia Şenkaya1, Zafer Çil2, Ömür Keskin1, Mehmet Emin Güneş1, Deniz Can Öztekin1
Pubmed: 36929802
Ginekol Pol 2023;94(4):298-302.


Objectives: In this study, our aim is to investigate the effect of CoronaVac vaccine on ovarian reserve in female patients followed up for infertility.
Material and methods: Our study is a retrospective study. Forty-six infertile patients who received two doses of CoronaVac vaccine one month apart and had not had a previous Covid 19 infection were included in the study. Anti-müllerian hormone (AMH) and folliculometry of 46 patients one month before CoronaVac vaccine and one month after the second dose of vaccine were compared.
Results: There was no statistically significant difference in the change of AMH level and follicle number before and after vaccination (respectively p = 0.366; 0.610).
Conclusions: Considering that having a COVID-19 infection has a negative effect on female fertility and causing ovarian damage in recent studies, vaccination is a rational and cost-effective approach to protect ovarian reserve. Knowing that the vaccine does not have a negative effect on fertility may increase the application of the vaccine in women of reproductive age.

Article available in PDF format

View PDF Download PDF file


  1. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223): 470–473.
  2. Zhu Na, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
  3. World Health Organization. Virtual press conference on COVID-19 – 11 March 2020. https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf (28.01.2022).
  4. Salzberger B, Buder F, Lampl B, et al. Epidemiology of SARS-CoV-2 infection and COVID-19. Internist (Berl). 2020; 61(8): 782–788.
  5. World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf (28.01.2022).
  6. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(2): 181–192.
  7. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6): 803–812.
  8. Mallapaty S. China COVID vaccine reports mixed results — what does that mean for the pandemic? Nature. 2021 [Epub ahead of print].
  9. Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020; 20(7): 442–447.
  10. Tesarik J. After corona: there is life after the pandemic. Reprod Biomed Online. 2020; 40(6): 760–762.
  11. Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, leydig and sertoli cells. Cells. 2020; 9(4).
  12. Wang T, Du Z, Zhu F, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020; 395(10228): e52.
  13. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683–690.
  14. Ali N. Relationship between COVID-19 infection and liver injury: a review of recent data. Front Med (Lausanne). 2020; 7: 458.
  15. Chu H, Bai T, Chen L, et al. Multicenter analysis of liver injury patterns and mortality in COVID-19. Front Med (Lausanne). 2020; 7: 584342.
  16. Li R, Yin T, Fang F, et al. Potential risks of SARS-CoV-2 infection on reproductive health. Reprod Biomed Online. 2020; 41(1): 89–95.
  17. Li K, Chen Ge, Hou H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online. 2021; 42(1): 260–267.
  18. Ding T, Wang T, Zhang J, et al. Analysis of ovarian injury associated with COVID-19 disease in reproductive-aged women in Wuhan, China: an observational study. Front Med (Lausanne). 2021; 8: 635255.
  19. Hansen KR, Knowlton NS, Thyer AC, et al. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008; 23(3): 699–708.
  20. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020; 114(6): 1151–1157.
  21. Kurmanova AM, Kurmanova GM, Lokshin VN. Reproductive dysfunctions in viral hepatitis. Gynecol Endocrinol. 2016; 32(sup2): 37–40.
  22. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005; 41(10): 1517–1524.
  23. Kallio ER, Helle H, Koskela E, et al. Age-related effects of chronic hantavirus infection on female host fecundity. J Anim Ecol. 2015; 84(5): 1264–1272.
  24. Stanley KE, Thomas E, Leaver M, et al. Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues. Fertil Steril. 2020; 114(1): 33–43.
  25. Fu J, Zhou B, Zhang L, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Mol Biol Rep. 2020; 47(6): 4383–4392.
  26. Illiano E, Trama F, Costantini E. Could COVID-19 have an impact on male fertility? Andrologia. 2020; 52(6): e13654.
  27. Khalili MA, Leisegang K, Majzoub A, et al. Male fertility and the COVID-19 pandemic: systematic review of the literature. World J Mens Health. 2020; 38(4): 506–520.
  28. Berenson AB, Chang M, Hirth JM, et al. Intent to get vaccinated against COVID-19 among reproductive-aged women in Texas. Hum Vaccin Immunother. 2021; 17(9): 2914–2918.
  29. Orvieto R, Noach-Hirsh M, Segev-Zahav A, et al. Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle? Reprod Biol Endocrinol. 2021; 19(1): 69.
  30. Bowman CJ, Bouressam M, Campion SN, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol. 2021; 103: 28–35.